Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01353027 | Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus | PHASE1 | COMPLETED | 30 | — | — | May 1, 2010 | Nov 1, 2011 | Mar 28, 2012 | 1 | United States |
The frequency and severity of adverse events will be monitored through 28 days post administration.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| AVI-6002 | EXPERIMENTAL | Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Normal saline |
| AVI-6002 | DRUG | Single intravenous administration |
Inclusion Criteria: * Male or female and between the ages of 18 and 50 years in good general health * Volunteers must be willing to use barrier methods of contraception or be of non-childbearing potential * Volunteers must be willing to undergo a urine screen for drugs of abuse Exclusion Criteria:...